Crinetics Pharmaceuticals to Report Q1 2026 Results on May 7

The pharmaceutical company will host a conference call to discuss financial results and provide a business update.

Apr. 9, 2026 at 2:37am

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of pharmaceutical pill bottles and vials in shades of blue, grey, and white against a clean white background, conceptually representing Crinetics Pharmaceuticals' focus on developing innovative treatments for endocrine diseases.Crinetics Pharmaceuticals' pipeline of novel endocrine disease therapies takes center stage in this polished studio still life.San Diego Today

Crinetics Pharmaceuticals, Inc. announced that it will report its first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. The company will host a conference call at 4:30 p.m. ET that day to discuss the financial results and provide a business update.

Why it matters

As a publicly traded pharmaceutical company, Crinetics' quarterly financial performance and business updates are closely watched by investors and analysts to gauge the company's progress and outlook. The release of Q1 2026 results will provide insight into Crinetics' operations, pipeline development, and commercial performance.

The details

Crinetics will report its Q1 2026 financial results after the market closes on May 7, 2026. The company will then host a conference call at 4:30 p.m. ET that same day for management to discuss the results and provide a business update. Participants can access the call via dial-in numbers or through a live webcast on the company's website.

  • Crinetics will report Q1 2026 financial results on Thursday, May 7, 2026 after the market closes.
  • The company will host a conference call at 4:30 p.m. ET on May 7, 2026 to discuss the results.

The players

Crinetics Pharmaceuticals, Inc.

A global pharmaceutical company focused on transforming the treatment of endocrine diseases and endocrine-related tumors.

Gayathri Diwakar

Head of Investor Relations at Crinetics Pharmaceuticals.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching Crinetics' Q1 2026 financial results and conference call for updates on the company's pipeline progress, commercial performance, and overall business outlook.

The takeaway

Crinetics Pharmaceuticals' upcoming Q1 2026 financial report and conference call will provide important updates on the company's efforts to develop novel therapies for endocrine diseases and tumors, a key focus area for the pharmaceutical firm.